Bridges Investment Management Inc. acquired a new position in shares of West Pharmaceutical Services, Inc. (NYSE:WST – Free Report) in the 2nd quarter, according to its most recent disclosure with the SEC. The fund acquired 623 shares of the medical instruments supplier’s stock, valued at approximately $205,000.
A number of other institutional investors and hedge funds have also recently modified their holdings of WST. Artisan Partners Limited Partnership boosted its position in shares of West Pharmaceutical Services by 23.2% during the 4th quarter. Artisan Partners Limited Partnership now owns 1,961,063 shares of the medical instruments supplier’s stock worth $690,530,000 after acquiring an additional 369,792 shares in the last quarter. APG Asset Management US Inc. acquired a new position in West Pharmaceutical Services in the fourth quarter valued at approximately $88,227,000. LGT Group Foundation purchased a new position in West Pharmaceutical Services in the second quarter valued at approximately $68,854,000. Liontrust Investment Partners LLP acquired a new stake in West Pharmaceutical Services during the second quarter worth approximately $64,196,000. Finally, TD Asset Management Inc lifted its position in shares of West Pharmaceutical Services by 38.4% during the 4th quarter. TD Asset Management Inc now owns 659,560 shares of the medical instruments supplier’s stock worth $232,244,000 after buying an additional 183,153 shares during the last quarter. Institutional investors and hedge funds own 93.90% of the company’s stock.
Insider Buying and Selling
In other West Pharmaceutical Services news, VP Charles Witherspoon sold 1,029 shares of the business’s stock in a transaction that occurred on Monday, August 19th. The stock was sold at an average price of $300.00, for a total value of $308,700.00. Following the completion of the sale, the vice president now owns 1,478 shares in the company, valued at $443,400. The sale was disclosed in a document filed with the SEC, which is available through this link. 0.53% of the stock is currently owned by company insiders.
West Pharmaceutical Services Trading Down 1.0 %
West Pharmaceutical Services (NYSE:WST – Get Free Report) last released its quarterly earnings data on Thursday, July 25th. The medical instruments supplier reported $1.52 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.74 by ($0.22). West Pharmaceutical Services had a net margin of 18.25% and a return on equity of 19.17%. The company had revenue of $702.10 million during the quarter, compared to analyst estimates of $729.36 million. During the same quarter in the prior year, the company earned $2.11 EPS. The business’s revenue was down 6.9% on a year-over-year basis. On average, equities analysts forecast that West Pharmaceutical Services, Inc. will post 6.42 EPS for the current fiscal year.
West Pharmaceutical Services Company Profile
West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.
Featured Articles
- Five stocks we like better than West Pharmaceutical Services
- What is a Dividend King?
- 3 Stocks That Could Rise on European Bank Interest Rate Cuts
- 3 Warren Buffett Stocks to Buy Now
- Take Advantage of Village Farms Stock as Cannabis Market Evolves
- Unveiling The Power Of VWAP: A Key Indicator For Traders
- MarketBeat Week in Review – 9/16 – 9/20
Want to see what other hedge funds are holding WST? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for West Pharmaceutical Services, Inc. (NYSE:WST – Free Report).
Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with MarketBeat.com's FREE daily email newsletter.